3
Registered trials
2
Recruiting
3
Unique sponsors
5
Unique IMPs
3
Commercial trials
Drug classes (ATC)
V
Various (ATC V)
1
—
ATC code not specified
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
3 substances
Radiopharmaceutical
1 substance
Monoclonal antibody (immune)
1 substance
Phase II:
1
Phase I (Other):
1
Phase I (First in Human):
1
Phase II
1 trial-
EndedDaiichi Sankyo Inc. CommercialVALEMETOSTAT TOSILATE
Phase I (Other)
1 trial-
RecruitingITM Solucin GmbH CommercialL-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) EDOTREOTIDE
Phase I (First in Human)
1 trial-
RecruitingMoonLake Immunotherapeutics AG CommercialIMSIDOLIMAB; MPS-112, MPS-106, MPS-213, MPS-102, MPS-216, MPS-103, MPS-215, MPS-214, D-ALA-LYS-CHA-VAL-ALA-ALA-TRP-THR-LEU-LYS-ALA-ALA-D-ALA, MPS-200
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| ITM Solucin GmbH | Commercial | 1 | Phase I (Other) | 1 |
| Daiichi Sankyo Inc. | Commercial | 1 | Phase II | 0 |
| MoonLake Immunotherapeutics AG | Commercial | 1 | Phase I (First in Human) | 1 |
New trials by year
2021
1
2022
1
2025
1